News Ticker

[ October 3, 2023 ] Leaniar LLC Attains UiPath Platinum Partner Status, Pioneering Automation in Healthcare, Manufacturing, Supply Chain, and E-Commerce Los Angeles Biotech News
[ October 3, 2023 ] Serimmune Announces Use of Its SERA Platform in Study Designed to Identify Features of Long COVID Through Immune Profiling Los Angeles Biotech News
[ October 3, 2023 ] ImmPACT Bio to Present at Cell & Gene Meeting on the Mesa Los Angeles Biotech News
[ October 3, 2023 ] Capsida Biotherapeutics Enters Strategic Collaboration With Kate Therapeutics to Manufacture KateTx’s Next-Generation Gene Therapies Los Angeles Biotech News
[ October 3, 2023 ] BioBam Launches OmicsBox 3.1: Revolutionizing Omics Data Analysis Los Angeles Biotech News

LIB’s cholesterol-busting drug aces second phase 3 trial, keeping Amgen blockbuster in its sights

August 29, 2023 Los Angeles Biotechnology Network News Los Angeles Biotech News Comments Off

LIB’s cholesterol-busting drug aces second phase 3 trial, keeping Amgen blockbuster in its sights
ntaylor
Tue, 08/29/2023 – 06:12
Click here to view original post

Copyright © 2023 Biotech Networks, LLC